# About Me

Experienced professional with a strong background in non-clinical research and project management within biotech and pharma. Extensive expertise in coordinating cross-functional teams, streamlining workflows, and implementing data management systems. Proficient in Python, R, and SQL, with a proven ability to combine technical and managerial skills to drive innovation and deliver impactful results in biomedical research and drug development.

## Professional Experience 
**Project Manager Intern – [Boehringer Ingelheim](https://www.boehringer-ingelheim.com/), Ridgefield, CT (_May 2024 – Aug 2024_)**
- **Coordinated cross-functional collaboration** among scientists, IT specialists, and vendors (e.g., Genedata, Certara) to streamline R&D data workflow, accelerate decision-making, and align project delivery with strategic goals.
- **Implemented lab management software** in collaboration with IT staff and engineers, optimizing account setups, data alignment, instrument integration, and automated reporting, reducing manual time, effort and errors by 90%.
- **Delivered 4 training sessions** to 80+ users across US and European teams, presenting materials and updates to drive digital tool adoption, enhance collaboration, and facilitate departmental digital transformation.


**Associate Project Manager – Protech Pharmaservices Corporation (acquired by [Novotech](https://novotech-cro.com/contact?utm_source=Google&utm_medium=Search&utm_campaign=SN_Brand_US&utm_id=20968953014&gad_source=1&gbraid=0AAAAAqxLUiW7xn1gsbUdccQZmyOjiZxeG&gclid=Cj0KCQiA7NO7BhDsARIsADg_hIYkttxnKKJZKhrSbBtmLxXCRZLi9x85UNpQXpFXVB_tE2TrpSZlsKcaAipFEALw_wcB)), Taipei, Taiwan (_Jan 2019 – Dec 2019_)**
- **Managed 10+  clinical trials regarding central lab services**, coordinating cross-functional teams (clinical, lab, biostatistics, and regulatory affairs) to achieve project deliverables within established timeframes.
- Fostered collaborative relationships as the primary liaison for 8 sponsors, 6 CROs, and 3 vendors, **managing outsourced assays**, resolving logistical challenges, and providing project updates. Built trust to secure payments, increase revenue, and ensure seamless study setup and execution.
- **Trained clinical site personnel** on biospecimen workflows and lab processes, including sample handling, documentation, and shipping protocols, reducing study-related queries to under 5%.
- **Streamlined biospecimen operations** by overseeing import/export permit applications and creating 3+ work instructions for study setup, data documentation, and specimen transportation, improving accuracy and reducing run time by 20-30%.
- **Supervised in-house LIMS implementation** (Laboratory Information Management System), defining data specification, and resolving issues to automate data transformation and report, enabling timely patient report reviews by clinical investigators.

**Associate Project Manager – [Calgent Biotechnology](https://www.calgent.com/), Taipei, Taiwan (_June 2018 – Dec 2018_)**
- **Managed collaborations with CROs** and CMOs, ensuring **GLP non-clinical study compliance** and GMP production for clinical trial readiness, contributing to the regulatory pathway for multiple myeloma treatment.
- Compiled regulatory documents, including the **Investigator's Brochure**, securing orphan drug designation for a novel therapeutic.

**Associate Scientist – [Lumosa Therapeutics](https://www.lumosa.com.tw/), Taipei, Taiwan (_June 2014 – Aug 2016_)**
- **Led non-GLP preclinical animal studies (PK, PD, toxicity)** to evaluate new drug candidates, optimizing experimental workflows, and delivering data-driven recommendations for drug development strategies.
- Synthesized experimental data into reports **supporting US IND application**, enabling a Phase I/First-in-Human trial for a drug candidate targeting acute ischemic stroke, addressing the critical unmet need for treatment beyond the 3.5-hour window.

## Additional Experience 
**Data Analysis Intern – Harvard Medical School, Boston, MA    	    				      (_June 2023 – Aug 2023_)**
- Conducted genomic analysis on lung adenocarcinoma cohorts, identifying unique mutational signatures and potential biomarkers among Taiwanese population using Python and R.

**Associate Scientist – FusionVax Biotechnology, Taipei, Taiwan				 	      (_June 2011 – June 2013_)**
- Designed and executed experiments using mouse xenograft models, cell viability assays, and immunohistochemistry to test new anti-tumor agents for breast and HPV-associated cancers, supporting a strategic partnership with a US-based vaccine company Advaxis.

**Early-Stage Researcher – Biomedical Research Foundation, Athens, Greece	 	                	          (_Jan 2010 – Oct 2010_)**
- Investigated the role of chaperone-mediated autophagy (CMA) in neurodegeneration, identifying Lamp2a as a potential therapeutic target for Parkinson’s disease through in vivo and in vitro models.

## Education
- M.S., Bioinformatics, Northeastern University, Boston, MA (_Aug 2024_) 
- M.S., Anatomy and Cell Biology, National Taiwan University, Taipei, Taiwan (_2005_)
- B.S., Zoology, National Chung Hsing University, Taichung, Taiwan (_2002_)

## Certification
- [Google Project Management](https://coursera.org/share/1dd7b01d7e3c647f48857737a44774aa) (Coursera)

## Skills
- **Technical Skills**: Python, R, SQL, Bash/Shel, Unix/Linux, High-performance computing (Slurm cluster), Git/GitHub, Jira  
- **Laboratory Skills**: DNA/RNA extraction, RT-PCR, gel electrophoresis, western blotting, cell culture, immunohistochemistry, immunofluorescence, H&E, tissue sectioning, rat/mice microsurgery, ELISA

## Publications
- Tsai MJ, **Peng HY**, Hsu YH. Mutational Signature Insights into Non-Smoking Female Lung Adenocarcinoma. (Manuscript in preparation)
- Kuo TH, **Peng HY**, Fu RH, Yeh SW and Wendy Huang (2016) A Novel Dual Function Molecule for the Treatment of Acute Ischemic Stroke. Stroke, (47), A173.
- Xilouri M, **Peng HY**, Stefanis L. (2012) Chaperone-mediated autophagy (CMA) in neurons. In Yue Z & Chu CT (Eds.), Autophagy of the Nervous System (pp.87 - 103), World Scientific Publishing Co.
- Xilouri M, **Peng HY**, Papasilekas T, Vekrellis K, Stefanis L (2011) Targeting the CMA pathway in neuronal cells mitigates alpha-synuclein induced toxicity. Journal of Neurochemistry, 118.
- Tsuei DJ, Lee PH, **Peng HY**, Lu HL, Su DS, Jeng YM, Hsu HC, Hsu SH, Wu JF, Ni YH, Chang MH. (2011) Male germ cell-specific RNA binding protein RBMY: A new oncogene explaining male predominance in liver cancer. PLoS ONE, 6 (11), e26948.
